Bioceltech Therapeutics, Ltd. is a high-tech company which focuses on the development and application of new technology in immunotherapy. It is located in the key planning gathering area of Bio-High-Tech industry -- PKUCare Industrial Park, Zhongguancun Life Science Park, Beijing.
The core technology team consists of many senior immunotherapy experts from the University of Pennsylvania, Harvard University and other famous American immunotherapy centers and enterprises. They have engaged in the research and development, quality control, standardized production and clinical application management of immunotherapy such as CAR-T for nearly 20 years.
The team has cooperated with the Institute Of Hematology, Peking University People's Hospital since 2016 and together we successfully cured a 3-year-old patient with Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) by using HLA-haploidentical allogenic CAR-T cell therapy (T-cells of the patient's relatives).
umor biological therapy is a new approach of tumor therapy with remarkable curative effect, and it is a novel method of autoimmune anticancer treatment.
The inspection and evaluation of immune function are important for clinical guidance and monitoring, either for patients who receiving immunotherapy or for sub-health and normal people who receiving immune cell health care.
Recently，immunosenscence is becoming one of the hot topic in the research field of basic immunology and immunotherapy
Stem cells, with the potential of self-renewal and multi-directional differentiation, are the original cells of the organism. They can form various tissues and organs of human body. Under certain conditions, it can differentiate into many functional cells、tissue and organs. It is called “Universal cell” in medical field.
（CAR-T technology is a developed adoptive cell therapy in recent years, and it is recognized as a unique way to completely conquer human cancers. In August 2011, the American Journal of Bio-Translational Medicine and the New England Journal of Medicine reported that professor Carl H. June, who is a gene therapist at the University of Pennsylvania, had cured two patients with Advanced Chronic Lymphoblastic Leukemia (CLL) by using a modified autologous T-cell (CAR-T).
異體(tǐ)CAR-T“北京方案”再傳佳音(yīn)！白血病患兒治愈已3年  |
| 許中偉教授與原領導Carl June教授及其課題組共同發表CAR-T綜述文章 |
| 許中偉博士應聘為(wèi)北京大(dà)學免疫學系全球共探路 |
| Dr.Michael 出訪貝賽爾特公司并與首席科學家(jiā)許中偉教授參加“新生(shēng)物制(zhì)藥時(shí)代 |
| 球共探路：貝賽爾特CEO姚毅博士應邀參加第九屆财新峰會(huì) |
| 貝賽爾特首席科學家(jiā)許中偉教授、姚毅博士應邀參加“2018醫(yī)學免疫與臨床應用高(gāo)峰論壇” |
| 貝賽爾特首席科學家(jiā)許中偉教授受邀參加第三屆北京國際醫(yī)學工程大(dà)會(huì)暨國際醫(yī)藥人(rén)工智能大(dà)會(huì) |
| 貝賽爾特再添虎将---FDA姚毅博士擔任公司首席醫(yī)學總監 |
| 公司開(kāi)展細胞藥物GMP的實施研討(tǎo)活動 |
